Is Atea Pharmaceuticals, Inc. (AVIR) a Buy, Sell, or Hold?
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$4.7 USD
-$0.04 (-0.84%)
- Volume
- 341.64K
- Average Volume
- 333.85K
- Market Capitalization
- $376.13M
- P/E Ratio
- -2.23
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $6.45
- Year Low
- $2.78
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.89
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
60
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
34
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 1.72M
AVIR Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
AVIR Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Lucidi Bruno | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| Lucidi Bruno | director | 2026-06-18 | A-Award | 4.36 | 2026-06-23 |
| Lucidi Bruno | director | 2026-06-18 | A-Award | 0 | 2026-06-23 |
| Lucidi Bruno | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| BERGER FRANKLIN M | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| BERGER FRANKLIN M | director | 2026-06-18 | A-Award | 4.36 | 2026-06-23 |
| BERGER FRANKLIN M | director | 2026-06-18 | A-Award | 0 | 2026-06-23 |
| BERGER FRANKLIN M | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| Berman Howard | director | 2026-06-18 | A-Award | 4.36 | 2026-06-23 |
| Berman Howard | director | 2026-06-18 | A-Award | 0 | 2026-06-23 |
| DUNCAN BARBARA GAYLE | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| DUNCAN BARBARA GAYLE | director | 2026-06-18 | A-Award | 4.36 | 2026-06-23 |
| DUNCAN BARBARA GAYLE | director | 2026-06-18 | A-Award | 0 | 2026-06-23 |
| DUNCAN BARBARA GAYLE | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| Polsky Bruce | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| Polsky Bruce | director | 2026-06-18 | A-Award | 4.36 | 2026-06-23 |
| Polsky Bruce | director | 2026-06-18 | A-Award | 0 | 2026-06-23 |
| Polsky Bruce | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| Murphy Polly A. | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| Murphy Polly A. | director | 2026-06-18 | A-Award | 4.36 | 2026-06-23 |
| Murphy Polly A. | director | 2026-06-18 | A-Award | 0 | 2026-06-23 |
| Murphy Polly A. | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| Adams Jerome M. | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| Adams Jerome M. | director | 2026-06-18 | A-Award | 4.36 | 2026-06-23 |
| Adams Jerome M. | director | 2026-06-18 | A-Award | 0 | 2026-06-23 |
| Adams Jerome M. | director | 2026-06-18 | M-Exempt | 0 | 2026-06-23 |
| KIRSCH ARTHUR S | director | 2026-06-18 | A-Award | 4.36 | 2026-06-23 |
| KIRSCH ARTHUR S | director | 2026-06-18 | A-Award | 0 | 2026-06-23 |
| Murphy Polly A. | director | 2026-05-18 | P-Purchase | 4.1715 | 2026-05-21 |
| Murphy Polly A. | director | 2025-05-18 | P-Purchase | 4.1715 | 2026-05-20 |
| Corcoran Andrea | officer: See Remarks | 2026-03-11 | M-Exempt | 1.24 | 2026-03-13 |
| Corcoran Andrea | officer: See Remarks | 2026-03-11 | M-Exempt | 1.24 | 2026-03-13 |
| Horga Maria Arantxa | officer: Chief Medical Officer | 2026-01-31 | A-Award | 4.24 | 2026-02-03 |
| Horga Maria Arantxa | officer: Chief Medical Officer | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Horga Maria Arantxa | officer: Chief Medical Officer | 2026-01-31 | F-InKind | 4.24 | 2026-02-03 |
| Horga Maria Arantxa | officer: Chief Medical Officer | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Vavricka John | officer: Chief Commercial Officer | 2026-01-31 | A-Award | 4.24 | 2026-02-03 |
| Vavricka John | officer: Chief Commercial Officer | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Vavricka John | officer: Chief Commercial Officer | 2026-01-31 | F-InKind | 4.24 | 2026-02-03 |
| Vavricka John | officer: Chief Commercial Officer | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Hammond Janet MJ | officer: Chief Development Officer | 2026-01-31 | A-Award | 4.24 | 2026-02-03 |
| Hammond Janet MJ | officer: Chief Development Officer | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Hammond Janet MJ | officer: Chief Development Officer | 2026-01-31 | F-InKind | 4.24 | 2026-02-03 |
| Hammond Janet MJ | officer: Chief Development Officer | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Corcoran Andrea | officer: See Remarks | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Corcoran Andrea | officer: See Remarks | 2026-01-31 | F-InKind | 4.24 | 2026-02-03 |
| Corcoran Andrea | officer: See Remarks | 2026-01-31 | A-Award | 4.24 | 2026-02-03 |
| Corcoran Andrea | officer: See Remarks | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Sommadossi Jean-Pierre | director, officer: President, CEO, and Chairman | 2026-02-03 | M-Exempt | 1.24 | 2026-02-03 |
| Sommadossi Jean-Pierre | director, officer: President, CEO, and Chairman | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Sommadossi Jean-Pierre | director, officer: President, CEO, and Chairman | 2026-01-31 | F-InKind | 4.24 | 2026-02-03 |
| Sommadossi Jean-Pierre | director, officer: President, CEO, and Chairman | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Sommadossi Jean-Pierre | director, officer: President, CEO, and Chairman | 2026-02-03 | M-Exempt | 1.24 | 2026-02-03 |
| Foster Wayne | officer: EVP, Chief Accounting Officer | 2026-01-31 | A-Award | 4.24 | 2026-02-03 |
| Foster Wayne | officer: EVP, Chief Accounting Officer | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Foster Wayne | officer: EVP, Chief Accounting Officer | 2026-01-31 | F-InKind | 4.24 | 2026-02-03 |
| Foster Wayne | officer: EVP, Chief Accounting Officer | 2026-01-31 | M-Exempt | 0 | 2026-02-03 |
| Murphy Polly A. | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Murphy Polly A. | director | 2025-06-20 | A-Award | 3.25 | 2025-06-24 |
| Murphy Polly A. | director | 2025-06-20 | A-Award | 0 | 2025-06-24 |
| Murphy Polly A. | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| BERGER FRANKLIN M | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Duncan Barbara Gayle | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| BERGER FRANKLIN M | director | 2025-06-20 | A-Award | 3.25 | 2025-06-24 |
| Duncan Barbara Gayle | director | 2025-06-20 | A-Award | 3.25 | 2025-06-24 |
| BERGER FRANKLIN M | director | 2025-06-20 | A-Award | 0 | 2025-06-24 |
| Duncan Barbara Gayle | director | 2025-06-20 | A-Award | 0 | 2025-06-24 |
| BERGER FRANKLIN M | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Duncan Barbara Gayle | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Polsky Bruce | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Polsky Bruce | director | 2025-06-20 | A-Award | 3.25 | 2025-06-24 |
| Polsky Bruce | director | 2025-06-20 | A-Award | 0 | 2025-06-24 |
| Polsky Bruce | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Adams Jerome M. | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Adams Jerome M. | director | 2025-06-20 | A-Award | 3.25 | 2025-06-24 |
| Adams Jerome M. | director | 2025-06-20 | A-Award | 0 | 2025-06-24 |
| Adams Jerome M. | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Lucidi Bruno | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Lucidi Bruno | director | 2025-06-20 | A-Award | 3.25 | 2025-06-24 |
| Lucidi Bruno | director | 2025-06-20 | A-Award | 0 | 2025-06-24 |
| Lucidi Bruno | director | 2025-06-20 | M-Exempt | 0 | 2025-06-24 |
| Berman Howard | director | 2025-06-20 | A-Award | 3.25 | 2025-06-24 |
| Berman Howard | 2025-06-20 | 0 | 2025-06-24 | ||
| Kirsch Arthur S | director | 2025-02-20 | A-Award | 3.14 | 2025-02-24 |
| Kirsch Arthur S | director | 2025-02-20 | 0 | 2025-02-24 | |
| Kirsch Arthur S | director | 2025-02-20 | 0 | 2025-02-24 | |
| Hammond Janet MJ | officer: Chief Development Officer | 2025-01-31 | A-Award | 3.06 | 2025-02-04 |
| Hammond Janet MJ | officer: Chief Development Officer | 2025-01-31 | A-Award | 0 | 2025-02-04 |
| Hammond Janet MJ | officer: Chief Development Officer | 2025-01-31 | M-Exempt | 0 | 2025-02-04 |
| Hammond Janet MJ | officer: Chief Development Officer | 2025-01-31 | F-InKind | 3.06 | 2025-02-04 |
| Hammond Janet MJ | officer: Chief Development Officer | 2025-01-31 | M-Exempt | 0 | 2025-02-04 |
| Hammond Janet MJ | officer: Chief Development Officer | 2025-01-31 | A-Award | 0 | 2025-02-04 |
| Vavricka John | officer: Chief Commercial Officer | 2025-01-31 | A-Award | 3.06 | 2025-02-04 |
| Vavricka John | officer: Chief Commercial Officer | 2025-01-31 | A-Award | 0 | 2025-02-04 |
| Vavricka John | officer: Chief Commercial Officer | 2025-01-31 | M-Exempt | 0 | 2025-02-04 |
| Vavricka John | officer: Chief Commercial Officer | 2025-01-31 | F-InKind | 3.06 | 2025-02-04 |
| Vavricka John | officer: Chief Commercial Officer | 2025-01-31 | M-Exempt | 0 | 2025-02-04 |
| Vavricka John | officer: Chief Commercial Officer | 2025-01-31 | A-Award | 0 | 2025-02-04 |
| Horga Maria Arantxa | officer: Chief Medical Officer | 2025-01-31 | A-Award | 3.06 | 2025-02-04 |
| Horga Maria Arantxa | officer: Chief Medical Officer | 2025-01-31 | A-Award | 0 | 2025-02-04 |